Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer

Core Insights - Transgene's TG4050 has demonstrated 100% Disease-Free Survival (DFS) after a minimum of two years in the Phase I part of the clinical trial, confirming its clinical proof of principle [1][2] - The company is progressing with the Phase II part of the trial, expecting to complete patient randomization by the end of 2025, with initial immunogenicity data anticipated in H2 2026 and preliminary efficacy data in H2 2027 [3][4] Company Overview - Transgene is a biotechnology company focused on developing virus-based immunotherapies for cancer treatment, with TG4050 being its lead asset based on the myvac® platform [7][10] - The myvac® platform utilizes artificial intelligence from NEC to optimize antigen selection for individualized cancer treatment [8][10] Clinical Trial Details - The Phase I/II clinical trial for TG4050 targets HPV-negative squamous head and neck cancers, with approximately 80 patients expected to be enrolled and randomized [3][12] - The trial evaluates the efficacy of TG4050 as an adjuvant treatment following surgery and adjuvant therapy, with a focus on patients at risk of relapse [12] Future Developments - Transgene is preparing for a new Phase I trial in a second, undisclosed indication, aiming to initiate it in Q4 2025 [5][11] - The company is committed to advancing the development of TG4050 and enhancing its manufacturing capabilities to meet the demands of a competitive market [4][11]